Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma
Menée in vitro et à partir d'échantillons prélevés sur des patients atteints d'un myélome multiple, cette étude met en évidence une sous-population de cellules tumorales permettant de rendre compte de la résistance au bortezomib, un inhibiteur du protéasome
Proteasome inhibitors are key parts of our armamentarium against multiple myeloma, but the disease can become resistant through poorly defined mechanisms. In this issue of Cancer Cell, Leung-Hagesteijn and colleagues describe XBP1s− subpopulations of tumor cells that are resistant to bortezomib and may account for therapeutic failures in the clinic.
Cancer Cell , commentaire, 2012